logo
A dubious report on medical abortion was cited in NSW Parliament. Where did it come from?

A dubious report on medical abortion was cited in NSW Parliament. Where did it come from?

Multiple members of NSW Parliament have cited a flawed US report on the safety of a medical abortion pill, during the parliamentary debate on a bill to expand abortion access in the state.
The bill, which has passed both houses of parliament, allows nurse practitioners and endorsed midwives to prescribe abortion medication for early-stage pregnancies.
The recent paper, which suggested the medical abortion pill mifepristone carried more risk for women than previously thought, was cited by MPs on both sides of the divide — including Liberals, Labor, and independents.
ABC NEWS Verify contacted Australian experts for help interpreting the report. They variously labelled it "not scientific", "scaremongering" and "misinformation".
The document was published by a US-based conservative think tank named the Ethics and Public Policy Center (EPPC).
On its website it says "pushing back against the extreme progressive agenda, while building a consensus for conservatives" is one of its priorities.
The report was authored by the EPPC's director of data analysis, Jamie Bryan Hall, and its president, Ryan T. Anderson.
Both men formerly worked for one of Washington's most prominent right-wing think tanks, the Heritage Foundation — which controversially spearheaded Project 2025, sometimes labelled a "blueprint" for US President Donald Trump's second-term agenda.
The report claimed that one in 10 patients experience at least one serious adverse event within 45 days following an abortion involving the drug mifepristone.
Mifepristone is one of the drugs used in medical abortions in Australia, the US, and other countries. In Australia, the medication misoprostol is also prescribed as a second step.
The EPPC report further claimed the rate of serious adverse events after mifepristone abortions was "at least 22 times as high as the summary figure of 'less than 0.5 per cent' in clinical trials reported on the drug label".
University of Sydney gynaecology professor Kirsten Black said there were a number of issues with the report.
"This study in America was not published in a reputable journal," she said
"It's not really clear … where the data came from, how it was analysed. It hasn't been peer-reviewed.
"It's misinformation and it's just propaganda," she said.
On an FAQ page for the paper, the EPPC said the point of the study wasn't peer review, but replicability.
"We have made our study fully replicable for anyone who wants to analyze the insurance claims data," it said, claiming the dataset was available for purchase and the methodology was public.
A spokesman for the EPPC refused to disclose the source of the data to ABC NEWS Verify.
"There's nothing unique about our dataset — it's effectively all the insurance claims data that exist from 2017 to early 2024, both public and private," he said.
Asked about whether this contributed to what the FAQ page called a "replicability crisis" he said the data was clear and it was easy for anybody interested to replicate the study, but didn't address how those seeking to replicate the study would do so without knowing the exact source.
Despite these transparency shortcomings, ABC NEWS Verify found at least eight Liberal MPs, a Labor MP, and two independents all cited the report in parliament during the debate.
Independent MP Joe McGirr, who is medically trained, highlighted the report in parliament as an example of complication rates of mifepristone abortions, orally citing the report's authors, in a manner similar to how scientific studies are often referenced.
"A paper released in April this year by Hall and Anderson cites an analysis of American insurance claims data," he said during his speech.
In a statement to ABC NEWS Verify, Dr McGirr said he cited the study "in the context of showing a range of interpreted complication rates from the use of MS-2 Step, with other rates between 3 per cent and 6.6 per cent cited elsewhere."
He didn't answer a question on whether he probed the report's methodology before referencing it in parliament.
Labor's Greg Donnelly drew attention to the report under the guise of "medical, academic and other literature", without mentioning any of the academic literature, including systematic reviews, published in peer-reviewed journals.
Mr Donnelly did not respond to questions from ABC NEWS Verify about why he chose to quote the study.
Upper house Liberal MP Susan Carter used the report to suggest "the science is changing" and it "indicated a significantly higher serious adverse event rate from medical abortion than had previously been understood".
In an interview, she told ABC NEWS Verify she quoted the study because she found it "really interesting" as it was "the biggest study of its kind".
She said it was the first paper she had seen which relied on health insurance records to track a patient's progress after taking the pill.
"So you could actually, instead of tracking the procedure, which is what we do in Australia, this was tracking the woman."
Professor Black said that serious adverse events following mifepristone "happen in about one in 1,000 cases, two in 1,000, not 10 per cent".
Monash University women's health professor Danielle Mazza told ABC NEWS Verify that adverse events following mifepristone in Australia were very rare.
She said the EPPC report is "scaremongering by anti-abortionists".
Professor Mazza pointed to two systematic reviews that analysed data from several different studies and concluded that mifepristone and misoprostol are highly safe and effective.
Epidemiologist and science communicator Gideon Meyerowitz-Katz, who is a senior research fellow at the University of Wollongong, identified the lack of transparency around the source of the data used in the report as an issue, labelling the document as "very inadequate".
He called the paper's definition of a serious adverse event "bizarre".
The serious adverse event rate of "one in 10" (or 10.93 per cent, to be precise) includes some questionable categories.
For example, repeated (surgical) abortion — where a woman might need a surgical abortion after an incomplete medical one — makes up 2.84 per cent.
Dr Meyerowitz-Katz said this does not count as a serious adverse event.
"[Surgical abortions] have an extremely low rate of severe adverse events themselves … these are usually considered failures of the pill, not adverse events per se," he said.
Then there is the category of "ectopic pregnancy" (0.35 per cent) which occurs when a fertilised egg implants itself outside the uterus.
Mifepristone does not cause this condition, but the EPPC included it because the FDA specifies patients with the condition should not take it.
The EPPC later acknowledged to the Washington Post that not all ectopic pregnancy patients who are prescribed mifepristone, for example, while they're waiting for an ectopic pregnancy diagnosis, later took the drug.
There are also contradictions in the EPPC's description of its methodology, which claims to have analysed procedure codes in the insurance data.
For example, in the report, it states "other abortion-specific complications" includes codes "related to an abortion or miscarriage, as well as life-threatening mental health diagnoses".
In the FAQ, published days later, it said it excluded mifepristone use for miscarriage care from the dataset.
The EPPC spokesman asserted to ABC NEWS Verify that miscarriage was excluded from the report, without explaining the discrepancy.
The FAQ also said the report only included mental health codes which "met the criteria for life-threatening, in order to not overestimate that category".
But the spokesman conceded no patients were actually found under these codes.
Beyond these classification issues is the broader issue of causation — that is, whether the adverse events following mifepristone can be causally linked to the pill.
"The authors have assumed that every event following an abortion is related to that abortion, but they have no methodology that would allow them to make such an assessment," Dr Meyerowitz-Katz said.
He said the EPPC's FAQ didn't adequately explain the paper's methodology.
"How specifically did they define something that was 'life-threatening'? Which codes did they use?" Dr Meyerowitz-Katz said.
"Had the authors attempted to get this published in a high-quality scientific journal, these questions would have been asked by peer-reviewers.
"This [paper] is completely worthless as evidence and should be ignored by anyone who is interested in accurate health information."
It is unclear how so many NSW politicians came to quote the report during debate in parliament.
An adviser to Dr McGirr said, "it was provided by a parliamentary colleague" without giving additional context.
But the debate, which took place in the first two weeks of May, occurred shortly after the report's release, and amidst a push in the US to review the use of mifepristone in abortions.
Some US conservatives want tighter restrictions placed on the drug.
On April 24, US Food and Drug Administration Commissioner Marty Makary told PBS News he had "no plans to take action on mifepristone".
But that came with a caveat about "hypothetical" new data on the drug.
"If the data suggests something or tells us that there's a real signal … we can't promise we're not going to act on that data that we have not yet seen," Mr Makary said.
Days later, on April 28, the EPPC published its report, with insurance data questioning the safety of the drug.
On the same day, it was seized upon by Republican senator Josh Hawley, who has a long history of anti-abortion positions.
"It is time to revisit and restore the FDA's longstanding safety measures governing mifepristone," Senator Hawley said in a letter to Mr Makary.
On May 14, Health and Human Services Secretary Robert F. Kennedy Jr told a congressional hearing — in answer to a question from Senator Hawley — that he had ordered a complete review of the drug.
Dr Meyerowitz-Katz said the report was not a study, as it has been presented, but a "white paper", published by an "explicitly religious" organisation.
"[The report] is filled with issues, and the authors have failed to include basic data to allow us to know what they actually did," he said.
"All in all, this reads to me more like the political strategising of an explicitly anti-abortion group than any rational scientific analysis."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump to meet with Zelenskyy after no deal reached at Alaska summit
Trump to meet with Zelenskyy after no deal reached at Alaska summit

SBS Australia

time4 hours ago

  • SBS Australia

Trump to meet with Zelenskyy after no deal reached at Alaska summit

Listen to Australian and world news, and follow trending topics with SBS News Podcasts . Ahead of the high stakes meeting with Vladimir Putin, US President Donald Trump said he would know within two minutes of meeting the Russian leader whether it would be a success. It took almost three hours before the leaders emerged from the meeting behind closed doors. It was the first face-to-face meeting between Mr Trump and Mr Putin since 2019, with the Russian leader ostracised by Western leaders since Russia's full-scale invasion of Ukraine in 2022. After their meeting, Mr Trump and Mr Putin emerged to speak before reporters in Anchorage, but they took no questions. "I believe that we had a very productive meeting. There were many, many points that we agreed on - most of them. I would say. A couple of big ones that we haven't quite got there. But we have made some head way. There is no deal until there is a deal. I will call up NATO in a little while. I will of course call up President Zelenskyy." Mr Trump later told Fox News that he rated the meeting a 10 out of 10 - even though he revealed no details of the points of agreement and disagreement. "There is not that much. There is one or two significant items (of disagreement). But I think they can be reached. Not it is really up to President Zelenskyy to get it done. And I would also say the European nations. They have to get involved a little bit. But it is up to President Zelenskyy. And if they like, I will be at the next meeting. They are going to set up a meeting between President Zelenskyy, President Putin and myself, I guess. Not that I want to be there, but I want to make sure that it gets done. We have a pretty good chance of getting it done." It is a change in the tone Mr Trump had a few weeks ago when he issued a August 8 deadline for Mr Putin to show a genuine commitment to a ceasefire - or face stronger sanctions. At the post-meeting press conference, Mr Putin was keen to cast the meeting as a success for him - in receiving the invitation, but also on the prospect of a Russian-US economic reset. "I expect that today's agreement will be the starting point - not only for the solution of the Ukrainian issue. But will also help us bring back business and pragmatic relations between Russia and the US." He says he has not shifted in his position on the full-scale invasion in Ukraine. "We're convinced that in order to make the settlement lasting long-term, we need to eliminate the primary roots, the primary causes of the conflict. And we have said it multiple times, to consider all legitimate concerns of Russia and to reinstate a just balance of security in Europe - and in the world on a whole." And at the end of the press conference, Mr Putin was eager to secure another meeting with the US President. Donald Trump: "Thank you very much Vladimir." Vladimir Putin: "Next time in Moscow." Donald Trump: "Oh, that's an interesting one! I will get a little heat on that one but I could see it possibly happening. Thank you very much Vladimir. Thank you all! Thank you!" Vladimir Putin: Thank you so much." Matthew Sussex is a fellow at the Australian National University's Strategic and Defence Studies Centre. He says there was a lot of theatre and optics involved in the high stakes visit - and Mr Putin got what he wanted. "Yes, it's certainly a win for Vladimir Putin. The optics of it were that, you know, he came to American territory, but American territory in Alaska, which of course previously was part of the Russian Federation and there was a lot of media talk in Russia and billboards going up saying, you know, Alaska is Russian and we will take that back. So he got a photo opportunity with Donald Trump. So it makes him look, look respected and valued and making the American president travel all the way to Anchorage to meet him. And at the same time, he basically dodges those sanctions that Trump had threatened." Mark Cancian is a senior adviser at the Center for Strategic and International Studies in Washington DC. He says despite the convivial language between Mr Trump and Mr Putin, the Alaska summit was planned haphazardly from start to finish. "The press conference was startling - even bizarre - in the sense that the meeting was expected to last maybe six hours and broke up after about three. Then the press conference was called very abruptly. The journalists race into the room. The parties come on stage and speak their piece. Putin starts off and Trump responds, and then they trip off after a couple of minutes, they take no questions and Putin gets on his airplane, flies away. And I don't think anyone quite expected a result like that. On the other hand, the words spoken were very friendly. Both Putin and Trump were encouraging about the future, but vague. And this is clearly the first step on, you know, what could be a long journey." He says negotiations to end wars can take a long time to finalise, but there is a positive for Ukraine in that the worst outcome was avoided. "Another encouraging thing was Trump saying that the Europeans and Ukraine, President Zelenskyy, had to be part of this agreement, and that had not come through quite clearly again about a week ago. The concern is that the pressure will go on to Zelenskyy to give up territory, to make an end to the conflict and get it over with as Trump would say. The Ukrainians are very reluctant to give up territory." Ukrainian leader Volodymyr Zelenskyy says he has been briefed on the Alaska meeting in a phone call with Mr Trump. The call also ended with an invitation for him to come to Washington DC on Monday (18 August local time). He says he has accepted the invitation and looks forward to discussing "all of the details regarding ending the killing and the war".

How rate cut could impact Melb house prices in coming weeks
How rate cut could impact Melb house prices in coming weeks

News.com.au

time7 hours ago

  • News.com.au

How rate cut could impact Melb house prices in coming weeks

Experts are forecasting the Reserve Bank's latest rate cut could deliver bonuses worth tens of thousands of dollars to some Victorian home sellers' pockets in coming weeks. It's expected many buyers will race to secure a home following the RBA's 0.25 percentage point rate cut on Tuesday. Apollo Auctions Australasia general manager and master auctioneer Greg Brydon said a lot of homeseekers were hoping to purchase sooner rather than later. 'Buyers will say to themselves, 'Even if I pay $5000, $10,000, $20,000 more than I wanted to, at least I won't have to compete with a new flood of buyers in the next four to six weeks,' Mr Brydon said. With pre-approved home loans generally expiring within a standard three-month time frame, buyers approved for a loan after the latest rate cut would have a bit more money to play with, he said. But Mr Brydon added that if the traditionally-busier spring market was flooded with new stock, there could be less competition among buyers – resulting in a potential scenario where they would not necessarily need to spend more to secure a property. Ray White Victoria chief auctioneer Jeremy Tyrrell said Melbourne home prices 'are slowly coming back and increasing'. 'We've seen a lot of investors from interstate starting to put their eyeballs back on Melbourne at the moment,' Mr Tyrrell noted. He said last week's rate cut would boost confidence among both buyers and sellers. 'I don't think we'll see the full effects of that in the this week immediately, but I think as people start to take full advantage of those interest rate cuts – I'd say the next two to four weeks – we should start to see an impact of buyers certainly having slightly deeper pockets and new entrants to the market with confidence to buy,' he said. With Victorian sale stock levels down 10 to 15 per cent since winter 2024, he is expecting to see more listings pop up as the weather warms up. 'I believe a lot of people have been holding back and waiting for those interest rate cuts and spring,' Mr Tyrrell said. 'And I think those two coming together, we should start to see an influx of property, but at the same time, we'll start to see an influx of buyers with more confidence.' According to PropTrack, Victoria recorded a preliminary 77.5 per cent clearance rate from 476 early auction results this week. About 1028 homes across the state are slated to go under the hammer next week.

‘Preventable': Disturbing statistics reveal deadly problem across major state
‘Preventable': Disturbing statistics reveal deadly problem across major state

News.com.au

time10 hours ago

  • News.com.au

‘Preventable': Disturbing statistics reveal deadly problem across major state

Victoria has been rocked by the highest number of fatal overdoses in a decade, with nearly 600 residents dying from drug overdoses last year alone. Ten years ago, illicit drugs contributed to less than half of all overdose deaths. In 2024, the Coroners Court found this figure increased to 65.6 per cent. Ten years ago, illicit drugs contributed to less than half of all overdose deaths. In 2024, the Coroners Court found this figure increased to 65.6 per cent. It's a figure increasing yearly, with 584 Victorian residents dying from drug overdoses in 2024, up from 547 the year before and 552 in 2022. Heroin contributed to 248 deaths in the state, and 215 deaths were related to methamphetamine – a stat that has tripled since 2015. The majority of all overdose deaths occurred in metropolitan Melbourne, with about 75 per cent being unintentional. Monash University Associate Professor Shalini Arunogiri told NewsWire the bleak new figures were a reminder of the lack of treatment available for opioid addictions. 'Each of these 584 deaths represents a life lost unnecessarily,' she said. 'Behind every statistic is someone's loved one, a friend, a sibling, a parent.' Worryingly, the majority of the fatal overdoses were men, who made up two-thirds of total deaths over the past decade. Ms Arunogiri said there was a 'strong connection' between drug abuse and mental health, especially if people lacked access to mental health support and effective treatment and instead turned to substances as their 'only available relief'. 'People often turn to substances as a way of coping with untreated trauma, anxiety, depression or other psychological distress,' she said. 'This is why integrated care that treats both mental health and substance use is so important.' The increase in fatal heroin and methamphetamine overdoses was 'particularly concerning', Ms Arunogiri said, as harm reduction methods were available to prevent further deaths. 'The positive here is that solutions do exist, we just need to implement what works,' she said. 'Expanding medication-assisted treatment for opioid addiction must be a priority, given heroin's role as the top contributor.' Ms Arunogiri said lifesaving medications needed to be provided at a faster rate to prevent overdoses. 'Medications like methadone and buprenorphine can reduce the risk of overdose, but people often face long waits for care,' she said. 'Effective measures like drug checking and expanding access to opioid overdose reversal medications, such as naloxone, is also critical.' Penington Institute chief executive John Ryan said 'too many Australians are dying from preventable drug overdoses' and argued governments were '(refusing) to fully embrace measures to drive down this horrific toll'. 'We're still not spending enough money on proven harm reduction initiatives like drug testing, supervised injecting, community education and the wide provision of the anti-overdose drug naloxone,' he said. In May, the Victorian government introduced its take-home naloxone program, which was expanded across 50 needle and syringe program providers, including over the counter at pharmacies, at the Medically Supervised Injecting Room and via prescription to expand access to the medication. Ms Arunogiri said these were 'important steps' to preventing further harm. 'These evidence-based interventions are crucial, but we need further investment to make sure everyone can access the health care they need,' she said. 'The most devastating thing is that we know these deaths were preventable. 'We understand what works – effective medications, harm reduction services, early intervention, but we need to remove the barriers that keep people from accessing the healthcare we all deserve.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store